HAE — Haemonetics Corporation stock price and chart

Share this page

HAE

$118.28-2.48%

as of close, Oct 16, 2026

☾ AH $118.28 -2.48%

Haemonetics CorporationStock · HealthcareRussell 2000 0.1%Russell 3000 0.005%US Stock Market 0.005%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

40.050.060.070.080.090.0100.0110.0120.0130.005.0M10.0M$118.28

2026-10-16

Price$118.28

MA20$87.18

MA50$72.53

Vol4.8M

What would $1,000 invested in HAE be worth today? →

HAE returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $118.28
YTD price return: +47.57%
YTD total return: +47.57%
Next earnings: Nov 5, 2026 · Before open
Market cap: 5.4B2016-12 2.1B2026-10 5.4B+159.1% over the window
Enterprise value: 6.4B
Shares outstanding: 45.5M2016-07 51.3M2026-06 45.5M-11.3% over the window
52W low: $48.62
52W high: $123.77
From 52W high: -4.44%
From 52W low: +143.27%
52W range: 93%

Volume

Rel volume: 0.69×
30D volume: 681K
30D $ vol: 75.4M

Fundamentals

Sales (ttm): 1.4B2017-04 886.1M2026-06 1.4B+52.6% over the window
Sales/share: $29.722017-04 $16.892026-06 $29.72+75.9% over the window
EPS (ttm): $2.062016-07 -$1.292026-06 $2.06-259.9% over the window
FCF (ttm): 291.2M2016-07 42.7M2026-06 291.2M+582.5% over the window
FCF/share: $6.402016-07 $0.832026-06 $6.40+669.5% over the window
Book value/share: $18.402016-07 $13.952026-06 $18.40+31.9% over the window
Net margin: 7.12%2017-04 -3.0%2026-06 7.1%-340.2% over the window
ROE: 11.50%2016-07 -9.2%2026-06 11.5%-225.4% over the window
ROA: 4.07%2016-07 -5.0%2026-06 4.1%-181.7% over the window
Debt / equity: 1.40×2016-07 0.492026-06 1.40+183.2% over the window
Current ratio: 3.082016-07 2.462026-06 3.08+25.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +0.44%2025-06-28 → 2026-06-271.3B → 1.4B (+0.4% total)+3.54%2023-07-01 → 2026-06-271.2B → 1.4B (+11.0% total)+8.43%2021-07-03 → 2026-06-27903.4M → 1.4B (+49.7% total)n/a
Net income: -41.16%2025-06-28 → 2026-06-27163.3M → 96.3M (-41.1% total)-11.03%2023-07-01 → 2026-06-27136.6M → 96.3M (-29.5% total)+8.38%2021-07-03 → 2026-06-2764.5M → 96.3M (+49.3% total)n/a
FCF: +54.18%2025-06-28 → 2026-06-27189.2M → 291.2M (+53.9% total)+44.64%2023-07-01 → 2026-06-2796.6M → 291.2M (+201.4% total)+41.28%2021-07-03 → 2026-06-2752M → 291.2M (+459.5% total)+21.21%2016-07-02 → 2026-06-2742.7M → 291.2M (+582.5% total)
Shares: -5.58%2025-06-28 → 2026-06-2748.2M → 45.5M (-5.6% total)-3.56%2023-07-01 → 2026-06-2750.7M → 45.5M (-10.3% total)-2.28%2021-07-03 → 2026-06-2751M → 45.5M (-10.8% total)-1.19%2016-07-02 → 2026-06-2751.3M → 45.5M (-11.3% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -37.07%2025-06-28 → 2026-06-27$3.27 → $2.06 (-37.0% total)-8.17%2023-07-01 → 2026-06-27$2.66 → $2.06 (-22.5% total)+10.57%2021-07-03 → 2026-06-27$1.25 → $2.06 (+65.0% total)n/a
Sales/share: +6.38%2025-06-28 → 2026-06-27$27.94 → $29.72 (+6.4% total)+7.36%2023-07-01 → 2026-06-27$24.03 → $29.72 (+23.7% total)+10.95%2021-07-03 → 2026-06-27$17.70 → $29.72 (+67.9% total)n/a
FCF/share: +63.29%2025-06-28 → 2026-06-27$3.93 → $6.40 (+63.0% total)+49.98%2023-07-01 → 2026-06-27$1.91 → $6.40 (+236.0% total)+44.57%2021-07-03 → 2026-06-27$1.02 → $6.40 (+527.5% total)+22.67%2016-07-02 → 2026-06-27$0.83 → $6.40 (+669.5% total)
Book value/share: +0.47%2025-06-28 → 2026-06-27$18.31 → $18.40 (+0.5% total)+2.58%2023-07-01 → 2026-06-27$17.05 → $18.40 (+7.9% total)+6.78%2021-07-03 → 2026-06-27$13.27 → $18.40 (+38.7% total)+2.81%2016-07-02 → 2026-06-27$13.95 → $18.40 (+31.9% total)
Price: +137.79%2025-10-16 → 2026-10-16$49.77 → $118.28 (+137.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+9.50%2023-10-16 → 2026-10-16$90.08 → $118.28 (+31.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+11.09%2021-10-15 → 2026-10-16$69.91 → $118.28 (+69.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+13.22%2016-10-14 → 2026-10-16$34.15 → $118.28 (+246.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +137.79%2025-10-16 → 2026-10-16$49.77 → $118.28 (+137.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+9.50%2023-10-16 → 2026-10-16$90.08 → $118.28 (+31.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+11.09%2021-10-15 → 2026-10-16$69.91 → $118.28 (+69.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.22%2016-10-14 → 2026-10-16$34.15 → $118.28 (+246.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 57.4×2016-12 -35.382026-10 55.89-258.0% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 33.6×2016-12 -41.692026-10 33.57-180.5% over the window
Fwd P/E: 20.5×
P/S (ttm)Market cap ÷ TTM revenue.: 4.0×2016-12 2.282026-10 3.98+74.5% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.4×2016-12 2.772026-10 6.43+131.9% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 18.5×2016-12 33.952026-10 18.48-45.6% over the window
EV/EBITDA (fy): 23.6×
EV/Sales (ttm): 4.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 5.41%2016-10 2.9%2026-06 8.5%+189.8% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-27) ÷ shares_at(2025-06-28) = 1 − 45.5M ÷ 48.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 5.58%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (5.58%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-28) ($3.5B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 5.58%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($175M) ÷ today's market cap ($5.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.25%2016-10 0.0%2026-06 5.1%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $175M + TTM dividends $0) ÷ today's market cap ($5.4B). Same caveat as the cash buyback yield.: 3.25%2016-10 0.0%2026-06 5.1%

Vs own 10Y history

P/E: 56th
P/OI: 46th
P/S: 67th
P/B: 72nd
P/FCF: 12th

Bar = where today’s multiple sits in HAE’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-2.48%

-0.35%

+11.33%

+50.68%

YTD

+47.57%

+137.65%

+69.19%

Financial statements

Open full HAE financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

HAE — Haemonetics Corporation price, chart and key statistics